Therapeutic Trial of Metformin and Bortezomib in a Mouse Model of Tuberous Sclerosis Complex (TSC)
Open Access
- 21 February 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (2), e31900
- https://doi.org/10.1371/journal.pone.0031900
Abstract
Tuberous sclerosis complex (TSC) is a human genetic disorder in which loss of either TSC1 or TSC2 leads to development of hamartoma lesions, which can progress and be life-threatening or fatal. The TSC1/TSC2 protein complex regulates the state of activation of mTORC1. Tsc2+/− mice develop renal cystadenoma lesions which grow progressively. Both bortezomib and metformin have been proposed as potential therapeutics in TSC. We examined the potential benefit of 1 month treatment with bortezomib, and 4 month treatment with metformin in Tsc2+/− mice. Results were compared to vehicle treatment and treatment with the mTORC1 inhibitor rapamycin for 1 month. We used a quantitative tumor volume measurement on stained paraffin sections to assess the effect of these drugs. The median tumor volume per kidney was decreased by 99% in mice treated with rapamycin (p = 0.0004). In contrast, the median tumor volume per kidney was not significantly reduced for either the bortezomib cohort or the metformin cohort. Biochemical studies confirmed that bortezomib and metformin had their expected pharmacodynamic effects. We conclude that neither bortezomib nor metformin has significant benefit in this native Tsc2+/− mouse model, which suggests limited benefit of these compounds in the treatment of TSC hamartomas and related lesions.Keywords
This publication has 30 references indexed in Scilit:
- The Unfolded Protein Response: From Stress Pathway to Homeostatic RegulationScience, 2011
- Efficacy and Safety of Sirolimus in LymphangioleiomyomatosisNew England Journal of Medicine, 2011
- mTOR: from growth signal integration to cancer, diabetes and ageingNature Reviews Molecular Cell Biology, 2010
- Metformin Prevents Tobacco Carcinogen–Induced Lung TumorigenesisCancer Prevention Research, 2010
- Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent IκBα DegradationJournal of Biological Chemistry, 2010
- Important role of the LKB1–AMPK pathway in suppressing tumorigenesis in PTEN-deficient miceBiochemical Journal, 2008
- The TSC1–TSC2 complex: a molecular switchboard controlling cell growthBiochemical Journal, 2008
- AMPK Phosphorylation of Raptor Mediates a Metabolic CheckpointMolecular Cell, 2008
- Loss of the Tuberous Sclerosis Complex Tumor Suppressors Triggers the Unfolded Protein Response to Regulate Insulin Signaling and ApoptosisMolecular Cell, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008